|
|
|
| home > ebr > winter 2022 > ai does not drive novel drug discovery, science does |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
The use of AI in drug discovery, or any industry, is not a futuristic concept. However, it continues to receive media attention and is pushed by industry voices as a revolutionary fix for declining productivity. This is a fundamental problem because AI’s buzzword factor has created a misunderstanding of its potential and the incorrect perception that it is ahead of its time.
Nevertheless, people love a good innovation story.
To help put AI into perspective, a useful example is the recent automotive industry shake-up. For almost a decade, Tesla dominated headlines for pioneering electric vehicles and self-driving cars, creating an almost unobtainable futuristic aura. Many auto manufacturers dismissed this disruption and carried on producing gas-powered vehicles with only incremental innovation. We are quickly seeing that the future is progressively becoming more technology-enabled, and the rise of electric-powered vehicles is no exception. Those that are unwilling to change will not succeed. Moreover, those that were slow to change are now behind the market. Despite the hype, Tesla transformed the industry.
Using that analogy, we can say the same for the implementation of AI in the pharmaceutical industry. It has been dismissed by some, but will soon catalyse wider disruption.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Personalised Virtual Factory Tours Highlight Risks and Solutions for Improving Pharma/Biopharma Product Safety
Giesen, Germany, 13 March 2023 – Mettler-Toledo Product Inspection is launching new personalised virtual factory tours that will help pharma and biopharma manufacturers to improve quality assurance, regulatory compliance and consumer safety standards.
More info >> |
|
 |
White Papers |
 |
|
Characterisation of Biopharmaceutical Proteins
Reading Scientific Services Ltd (RSSL)
Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >> |
|
|
